Paul Sargos
@PaulSargos
🇫🇷 Radiation Oncologist 🔆Head of Department, Radiotherapy, Bergonie, Bordeaux 🔅Radiotherapy, Charlebourg-La Defense, Paris 🔆CC-AFU, GETUG, GFRU, ESTRO
Radiation vs systemic therapy for isolated pelvic recurrence after cystectomy. @AndreaNecchi & Comron Hassanzadeh join @UroDocAsh in a debate about optimal management of isolated pelvic recurrences after radical cystectomy. #WatchNow on UroToday > bit.ly/45e2hPP
📢 Our article on ADT duration + salvage RT in prostate cancer (URONCOR 06-24 trial) is now online! 🧠 Open access for 50 days: 👉 authors.elsevier.com/c/1lUCL_4oIYIT… #ProstateCancer #RadiationOncology #ClinicalResearch #URONCOR0624
🇧🇷J'aurai pu faire Paris Melbourne pour aller voir @_ShankarSiva.Mais non, c'était 20h de voyage pour Foz de Iguazu- Sao Luis... @VoeGOLoficial, quelle honte. 10 euros pour manger, pas de salon, pas un hôtel, pas un taxi. Plus jamais !! (Voilà j'ai râlé sur X) @AirFranceFR
STAMPEDE: ADT leads to high fracture rates in prostate cancer, esp. with mets. Zoledronic acid lowers fracture risk in metastatic, not non-metastatic. Should we add ZA or Deno in bone protecting dose? #prostatecancer #Oncology @Annals_Oncology @APCCC_Lugano @OncoAlert…
7/ 📝Summary ✅ AS *very safe* for all GG1 ✅ AS *very safe* for MRI-invisible GG2 non-cribriform ❌❌ Cribriform → do not offer AS ☑️ MRI-visible, non-cribriform GG2 → AS safe but 🤔could benefit from ⬆AS intensity?
Challenges in Defining Clinical Complete Response to Systemic Therapy in Muscle-invasive Bladder Cancer: Insights from the EORTC STARBURST Project euoncology.europeanurology.com/article/S2588-… The EORTC STARBURST-1 trial aims to refine treatment strategies for muscle-invasive bladder cancer by…
Would you like to participate in #FOCUS2025meetsSpain? Our partners are there, contact your medical delegate 📩 9 & 10 October 2025, Centre de congrès Pierre Baudis #Toulouse Registration : focus-meeting.fr #focusmeeting #urology #oncology #radiotherapy
Here are the highlights Many thanks to the amazing expert panel for the important input!
Excited to share our newest paper on digital pathology AI biomarkers in prostate cancer RT. In this work we: ▶️performed a systematic review ▶️checked ongoing trials ▶️collected an expert consensus sciencedirect.com/science/articl… Thanks @RO_GreenJournal for accepting this work
#CREST trial first interim analysis: Extending event-free survival and advancing care in high-risk #NMIBC. Neal Shore, MD, FACS @CURCMB joins @UroDocAsh @MDAndersonNews discussing CREST trial results demonstrating superior event-free survival with a hazard ratio of 0.68,…
The 10-year results of the HYPO-RT-PC trial, presented at #ESTRO25, confirm that ultra-hypofractionated #radiotherapy is a safe, effective option for localised #prostatecancer — with strong evidence and long-term follow-up to back it up. 👉 bit.ly/3T3jc0X
🚨Happy to share that I'm launching a new study called RAPSTAR - the first randomised, multicentre phase III trial comparing RAPN vs #SABR in patients who are candidates for surgery. Designed and led in 🇵🇱, just got funding from @AgencjaBadanMed and will start accrual soon!
@GETUG_Unicancer research & teaching days are on! Two days of discussion, updates and clinical trials development. Led by Prof Fizazi.
🇫🇷🇧🇪Ouverture des JER du @GETUG_Unicancer avec le débat sur la prise en charge des mCRPC. ✨ @RoubaudG @BertrandTOMBAL @Helissey4 @alicebernardt
@jbbeauval @PignotG @GPloussard @PouesselD @RoubaudG @MRoumiguie @PaulSargos @MRoupret @Achard_Verane @DrFelixGuerrero @OncoBellmunt @drenriquegrande @BenjaminPradere @gautiermarcq @BertrandTOMBAL @Ric_Campi @ZilliThomas
Presidents of FOCUS 2025 meets Spain : @Ecastromarcos @kbensalah35 🗓 9 & 10 October 2025 📍Centre de congrès Pierre Baudis #Toulouse 💻 registration : focus-meeting.fr/en/accueil-eng… #focusmeeting #focus2025meetsSpain #urology #oncology #radiotherapy
Active Surveillance for Screen-detected Low- and Intermediate-risk Prostate Cancer: Extended Follow-up up to 25 Years in the GÖTEBORG-1 Trial sciencedirect.com/science/articl… This long-term follow-up study from the GÖTEBORG-1 screening trial evaluated outcomes in 488 men with…